View in EDS

2317P Assessing the cost-effective price-range for pembrolizumab in treating PD-L1–high advanced non-small cell lung cancer (NSCLC) in South Africa.

Saved in:
Bibliographic Details
Title: 2317P Assessing the cost-effective price-range for pembrolizumab in treating PD-L1–high advanced non-small cell lung cancer (NSCLC) in South Africa.
Authors: Trapani, D.1 (AUTHOR), Ruff, P.2 (AUTHOR), Cairoli, F.3 (AUTHOR), Burrone, E.4 (AUTHOR), Segafredo, G.4 (AUTHOR)
Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1272-S1272. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2025.08.2933